Preoperative discrimination of malignant and benign ovarian masses using cfDNA fragmentomics and serum biomarkers.
A blood-based test catches ovarian cancers that standard biomarkers miss, potentially catching more cases early.
Preoperative discrimination of ovarian cancer from benign masses poses significant challenges, particularly in cases where serum biomarkers yield negative or nonspecific results. The cfDNA model also effectively detected cancers with CA125 and/or HE4 levels below conventional thresholds, and post hoc analyses demonstrated complementary discrimination when cfDNA was added to the Risk of Ovarian Malignancy Algorithm.
What the study was
- Study design
- Multicenter diagnostic validation study
- Population
- This multicenter observational diagnostic modeling study analyzed plasma cell-free DNA (cfDNA) from 743 participants across training, internal test, external test, and two exploratory cohorts using low-pass whole-genome sequencing.
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Molecular biomedicine
Why it surfaced
Multicenter diagnostic validation study assessed from PubMed metadata and abstract text; conservatively scored 8/10 under the v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.